Feasibility and antitumor efficacy in vivo, of simultaneously targeting glycolysis, glutaminolysis and fatty acid synthesis using lonidamine, 6-diazo-5-oxo-L-norleucine and orlistat in colon cancer

Documenti analoghi

• Reviving Lonidamine and 6-Diazo-5-oxo-L-norleucine to Be Used in Combination for Metabolic Cancer Therapy
  di: Cervantes-Madrid, Diana, et al.
  Pubblicazione: (2015)
• The combination of orlistat, lonidamine and 6-diazo-5-oxo-L-norleucine induces a quiescent energetic phenotype and limits substrate flexibility in colon cancer cells
  di: Schcolnik-Cabrera, Alejandro, et al.
  Pubblicazione: (2020)
• 6-Diazo-5-Oxo-l-Norleucine Inhibition of Escherichia coli
  di: Coggin, J. H., et al.
  Pubblicazione: (1965)
• Evaluating the Analgesic Effect of the GLS Inhibitor 6-Diazo-5-Oxo-L-Norleucine in Vivo
  di: Crosby, Heith A, et al.
  Pubblicazione: (2016)
• A combination of inhibitors of glycolysis, glutaminolysis and de novo fatty acid synthesis decrease the expression of chemokines in human colon cancer cells
  di: Schcolnik-Cabrera, Alejandro, et al.
  Pubblicazione: (2020)